Archived Content

Emerging Antibody and Protein Engineering Partnering Forum 

April 28-29, 2012 | Boston, MA

Detailed Agendas 

Day 1: Saturday, April 28th | Day 2: Sunday, April 29th

Click Here To Download Partnering Forum Brochure 

Particularly efficient for promoting discussion of partnerships, Cambridge Healthtech Insititute’s Biologics Partnering Forum on Emerging Antibody and Protein Engineering is designed for both the emerging companies with promising technology platforms and innovative approaches, as well as more established companies looking to collaborate as a way to gain access to novel technology and competitive products. Because of the focused nature and review process for selecting presenting companies, essentially every attendee will have significant shared interests with every other participant.

Reasons to Attend:

  • Opportunities for scheduled one-on-one meetings and unscheduled networking with three dozen company presenters and other participants
  • Approximately two-thirds of the presenting companies are focused on antibody engineering and one-third are focused on protein engineering
  • Company presenters were selected on the basis of a review of submitted proposals by the organizer and a strong panel of industry Program Advisors
  • Coverage of In vitro Antibody Development platforms, In vivo Transgenic Antibody Platforms, Bi-Specific and Multi-Specific Antibodies, Human-Derived Antibodies, Antibody Tools, Novel Antibodies in Development, Fusion Proteins, Novel Protein Scaffolds, and Screening and Design Platforms for Protein Engineering

Program Advisory Board Includes:

  • Brian Atwood, M.B.A., Managing Director, Versant Ventures

  • Sharon Cload, Ph.D., Vice President, Adnexus, Bristol Myers Squibb

  • Jon Ellis, Ph.D., Vice President, Business Development, Biopharmaceutical R&D and Platform Technology & Science, GlaxoSmithKline

  • Richard Harkins, Ph.D., Principal Scientist, Global Drug Discovery, Bayer Healthcare Pharmaceuticals

  • Margaret Karow, Ph.D., Executive Director, Protein Sciences, Amgen

  • Robert Kastelein, Ph.D., Vice President, Biologics Strategy, Merck Research Labs

  • Reid Leonard, Ph.D., Executive Director, Licensing, Merck Research Labs

  • Luke Li, M.D., Executive Director, Head of Global BioTherapeutic Technologies, Pfizer

  • Thomas Li, Ph.D., Senior Director, Technology, Roche Diagnostics

  • Kia Motesharei, Ph.D., Vice President, Business Development & Alliance Management, Dyax Corp.

  • Hilde Revets, Ph.D., Senior Research Fellow, Technology, Ablynx

  • Barry Springer, Ph.D., Head of External Research and Innovation, Biologics Research, Johnson & Johnson

  • Charles Wilson, Ph.D., Vice President, Global Head of Strategic Alliances, Novartis Institutes for Biomedical Research

  • Gordon Wong, Ph.D., Vice President, Business Development, Biogen-IDEC


Detailed Agendas  

Day 1: Saturday, April 28th | Day 2: Sunday, April 29th